ReviewShock (Augusta, Ga.)2026
Heat Shock Protein 90 in Sepsis-Induced Cardiomyopathy: Mechanistic Insights and Emerging Therapeutic Target.
Review in Shock (Augusta, Ga.), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
Sepsis-induced cardiomyopathy (SIC) is a form of cardiac dysfunction triggered by sepsis, whose pathogenesis primarily involves the release of endogenous danger signal molecules. As a key molecular chaperone, heat shock protein 90 (Hsp90) plays a fundamental role in stabilizing and activating client proteins to regulate essential cellular processes. Although the broader heat shock protein family has been studied in SIC, the specific mechanisms and therapeutic potential of Hsp90 remain to be fully elucidated. Hsp90 plays a crucial role in apoptosis, oxidative stress, mitochondrial autophagy, immune defense, and myocardial fibroblast function during heart dysfunction. This review systematically summarizes the structure and regulatory mechanisms of Hsp90 in SIC. Furthermore, we discuss recent advances in Hsp90 inhibitors, which was categorized as natural product-derived inhibitors, functional inhibitors, and structural disruptors, thereby providing a theoretical foundation and prospective strategies for novel therapeutic interventions against SIC.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.